In a syngeneic lung cancer model, the RBDdopa-BTZ conjugate showed potent antitumor efficacy against ACE2-expressing lung tumors with reduced toxicity in normal ACE2-expressing organs (liver, kidney, and heart). Here, ACE2 is linked to lung carcinoma.